GLP-1RA receptor agonists and SGLT2 inhibitors beneficial for managing type 1 diabetes
A new study has found an association between good type 1 diabetes management and the use of GLP-1RA receptor agonists and SGLT2 inhibitors in real-world practice.
During the experiment, a team of researchers examined the health outcomes of 104 adults living with type 1 diabetes who either used GLP-1RA receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is).
After one year of therapy, they found that GLP-1RA users had significant reductions in weight, HbA1c and total daily dose of insulin.
SGLT2i users also had statistically significant reductions in HbA1c and basal insulin, the study has reported.
The results state: “GLP-1RA users compared to SGLT2i users had greater reduction in weight (P = .027) while HbA1c reduction was comparable between the groups.
“Over a mean total duration of use of 29.5 months/patient for both groups, more SGLT2i users experienced diabetic ketoacidosis (DKA) (12.8 per cent vs 3.9 per cent).”
They added: “Therapy was discontinued because of adverse events 26.9 per cent of the time for GLP-1RA users vs 27.7 per cent for SGLT2i users.
“GLP-1RA and SGLT2i use in type 1 diabetes is associated with clinically relevant benefits. DKA remains a clinical concern with SGLT2i use, requiring careful selection and monitoring, with the risk to benefit ratio of treatment evaluated at an individual level.”
To read the study, click here.